Robert Bradsher
Concepts (296)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Blastomycosis | 36 | 2014 | 61 | 4.020 |
Why?
| Histoplasmosis | 12 | 2014 | 53 | 1.620 |
Why?
| Blastomyces | 17 | 2011 | 30 | 1.580 |
Why?
| Antifungal Agents | 19 | 2020 | 363 | 1.540 |
Why?
| Lung Diseases, Fungal | 16 | 2008 | 31 | 1.150 |
Why?
| Endemic Diseases | 3 | 2014 | 29 | 0.620 |
Why?
| Babesiosis | 1 | 2017 | 7 | 0.610 |
Why?
| Antigens, Fungal | 7 | 2011 | 31 | 0.610 |
Why?
| Mycoses | 6 | 2020 | 162 | 0.600 |
Why?
| Amphotericin B | 11 | 2010 | 122 | 0.590 |
Why?
| Blood Transfusion | 1 | 2017 | 138 | 0.550 |
Why?
| Cecal Diseases | 1 | 2014 | 7 | 0.500 |
Why?
| Colonic Diseases | 1 | 2014 | 13 | 0.490 |
Why?
| Adrenal Insufficiency | 1 | 2014 | 17 | 0.490 |
Why?
| Ulcer | 1 | 2014 | 23 | 0.490 |
Why?
| Azoles | 2 | 2010 | 28 | 0.380 |
Why?
| Central Nervous System Fungal Infections | 1 | 2010 | 3 | 0.370 |
Why?
| Ixodes | 1 | 2010 | 6 | 0.370 |
Why?
| Lyme Disease | 1 | 2010 | 28 | 0.360 |
Why?
| Borrelia burgdorferi | 1 | 2010 | 28 | 0.360 |
Why?
| Humans | 73 | 2020 | 54284 | 0.350 |
Why?
| HIV Infections | 1 | 2011 | 394 | 0.290 |
Why?
| Dermatomycoses | 4 | 1997 | 24 | 0.270 |
Why?
| Doxycycline | 3 | 2017 | 46 | 0.260 |
Why?
| Male | 40 | 2017 | 27334 | 0.250 |
Why?
| Histoplasma | 6 | 2011 | 29 | 0.240 |
Why?
| Tularemia | 2 | 2006 | 22 | 0.240 |
Why?
| Fatal Outcome | 3 | 2017 | 225 | 0.240 |
Why?
| Middle Aged | 24 | 2014 | 13088 | 0.230 |
Why?
| Ketoconazole | 7 | 1997 | 17 | 0.210 |
Why?
| Macrophages | 3 | 1994 | 405 | 0.210 |
Why?
| Diagnosis, Differential | 4 | 2014 | 1136 | 0.190 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2020 | 19 | 0.190 |
Why?
| Arkansas | 4 | 2020 | 2100 | 0.190 |
Why?
| Adult | 30 | 2010 | 14207 | 0.180 |
Why?
| Neoplasms | 2 | 2020 | 1316 | 0.180 |
Why?
| Sepsis | 3 | 2020 | 251 | 0.180 |
Why?
| Conjunctivitis, Bacterial | 1 | 1999 | 3 | 0.170 |
Why?
| Bacteremia | 2 | 2004 | 101 | 0.170 |
Why?
| Staphylococcus aureus | 4 | 2007 | 361 | 0.170 |
Why?
| AIDS-Related Opportunistic Infections | 2 | 1996 | 41 | 0.160 |
Why?
| Antibodies, Fungal | 2 | 1995 | 4 | 0.160 |
Why?
| Abscess | 1 | 1998 | 42 | 0.160 |
Why?
| Thoracic Vertebrae | 1 | 1998 | 46 | 0.160 |
Why?
| Babesia | 1 | 2017 | 6 | 0.150 |
Why?
| Quinine | 1 | 2017 | 7 | 0.150 |
Why?
| Clindamycin | 1 | 2017 | 15 | 0.150 |
Why?
| Platelet Transfusion | 1 | 2017 | 32 | 0.150 |
Why?
| Haemophilus Infections | 2 | 1994 | 6 | 0.150 |
Why?
| Treatment Outcome | 9 | 2014 | 5604 | 0.150 |
Why?
| Haemophilus influenzae | 2 | 1994 | 21 | 0.150 |
Why?
| Lumbar Vertebrae | 1 | 1998 | 105 | 0.150 |
Why?
| Female | 31 | 2012 | 28441 | 0.150 |
Why?
| Sensitivity and Specificity | 4 | 2011 | 923 | 0.140 |
Why?
| Cross Reactions | 3 | 2011 | 56 | 0.140 |
Why?
| Pulmonary Alveoli | 2 | 1987 | 20 | 0.140 |
Why?
| Methicillin Resistance | 2 | 2007 | 25 | 0.140 |
Why?
| Disease Outbreaks | 4 | 1992 | 124 | 0.140 |
Why?
| Itraconazole | 6 | 1997 | 45 | 0.140 |
Why?
| Immunoenzyme Techniques | 3 | 2011 | 165 | 0.140 |
Why?
| Aged, 80 and over | 6 | 2017 | 3431 | 0.140 |
Why?
| Imipenem | 1 | 1995 | 10 | 0.130 |
Why?
| Lymphocytes | 4 | 1985 | 168 | 0.130 |
Why?
| Immunocompromised Host | 3 | 2020 | 130 | 0.130 |
Why?
| Orchitis | 1 | 1994 | 3 | 0.130 |
Why?
| Epididymitis | 1 | 1994 | 5 | 0.130 |
Why?
| Fluconazole | 3 | 2003 | 35 | 0.130 |
Why?
| Radiography | 2 | 2010 | 524 | 0.120 |
Why?
| Lymphocyte Activation | 6 | 1990 | 197 | 0.120 |
Why?
| Remission Induction | 1 | 2014 | 221 | 0.120 |
Why?
| Diagnostic Errors | 1 | 2014 | 74 | 0.110 |
Why?
| Candidiasis | 2 | 2003 | 122 | 0.110 |
Why?
| Aged | 16 | 2007 | 10054 | 0.110 |
Why?
| Francisella tularensis | 2 | 2006 | 18 | 0.110 |
Why?
| Gentamicins | 2 | 2006 | 36 | 0.110 |
Why?
| United States | 5 | 2017 | 5217 | 0.110 |
Why?
| Coccidioidomycosis | 1 | 2012 | 7 | 0.110 |
Why?
| Otitis Media, Suppurative | 1 | 1992 | 8 | 0.110 |
Why?
| Cryptococcosis | 2 | 1989 | 21 | 0.100 |
Why?
| Ceftriaxone | 2 | 1988 | 29 | 0.100 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1048 | 0.090 |
Why?
| Tomography | 1 | 2010 | 5 | 0.090 |
Why?
| North America | 1 | 2010 | 68 | 0.090 |
Why?
| Anti-Bacterial Agents | 2 | 2007 | 820 | 0.090 |
Why?
| Head | 1 | 2010 | 77 | 0.090 |
Why?
| Focal Infection | 1 | 1989 | 1 | 0.090 |
Why?
| Meningoencephalitis | 1 | 1989 | 8 | 0.090 |
Why?
| Pseudomonas Infections | 2 | 2004 | 54 | 0.080 |
Why?
| Disease Reservoirs | 2 | 1987 | 7 | 0.080 |
Why?
| Pseudomonas aeruginosa | 2 | 2004 | 86 | 0.080 |
Why?
| Ischemic Attack, Transient | 1 | 1989 | 60 | 0.080 |
Why?
| Rodentia | 2 | 1987 | 19 | 0.080 |
Why?
| Fungemia | 2 | 2011 | 36 | 0.080 |
Why?
| Adolescent | 7 | 2010 | 6897 | 0.080 |
Why?
| Fresh Water | 1 | 1987 | 7 | 0.080 |
Why?
| Meningitis, Haemophilus | 1 | 1988 | 9 | 0.080 |
Why?
| Debridement | 1 | 2008 | 54 | 0.080 |
Why?
| Candida | 2 | 2003 | 67 | 0.080 |
Why?
| Staphylococcal Skin Infections | 1 | 2007 | 6 | 0.080 |
Why?
| Soft Tissue Infections | 1 | 2007 | 10 | 0.070 |
Why?
| Water | 1 | 1987 | 102 | 0.070 |
Why?
| Peritonitis, Tuberculous | 1 | 1986 | 1 | 0.070 |
Why?
| Community-Acquired Infections | 1 | 2007 | 42 | 0.070 |
Why?
| Practice Guidelines as Topic | 1 | 2010 | 492 | 0.070 |
Why?
| Phagocytosis | 4 | 1994 | 51 | 0.070 |
Why?
| Optic Neuritis | 1 | 2006 | 20 | 0.070 |
Why?
| Immunity, Cellular | 4 | 1994 | 80 | 0.070 |
Why?
| Staphylococcal Infections | 3 | 2007 | 300 | 0.070 |
Why?
| Salvage Therapy | 1 | 2006 | 145 | 0.070 |
Why?
| Triazoles | 1 | 2006 | 120 | 0.070 |
Why?
| Tetracyclines | 1 | 2005 | 7 | 0.070 |
Why?
| Blood | 1 | 1985 | 30 | 0.070 |
Why?
| Drug Therapy, Combination | 3 | 2005 | 426 | 0.070 |
Why?
| Recurrence | 3 | 1997 | 690 | 0.070 |
Why?
| Cefotaxime | 1 | 1984 | 3 | 0.060 |
Why?
| Skin Diseases, Infectious | 1 | 1984 | 7 | 0.060 |
Why?
| Leukocytes | 1 | 1984 | 85 | 0.060 |
Why?
| Health Facility Closure | 1 | 2004 | 4 | 0.060 |
Why?
| DNA Fingerprinting | 1 | 2004 | 38 | 0.060 |
Why?
| Microbial Sensitivity Tests | 3 | 2007 | 290 | 0.060 |
Why?
| Trismus | 1 | 1983 | 4 | 0.060 |
Why?
| Endocarditis | 2 | 1982 | 33 | 0.060 |
Why?
| Bacterial Infections | 1 | 1984 | 105 | 0.060 |
Why?
| Tetanus | 1 | 1983 | 8 | 0.060 |
Why?
| Infection Control | 1 | 2004 | 57 | 0.060 |
Why?
| Onygenales | 1 | 2003 | 1 | 0.060 |
Why?
| Male Urogenital Diseases | 1 | 2003 | 3 | 0.060 |
Why?
| Endocarditis, Bacterial | 1 | 1984 | 44 | 0.060 |
Why?
| Female Urogenital Diseases | 1 | 2003 | 6 | 0.060 |
Why?
| Magnetic Resonance Imaging | 2 | 2010 | 1604 | 0.060 |
Why?
| Pneumonia | 3 | 1991 | 129 | 0.060 |
Why?
| Streptococcal Infections | 1 | 1984 | 58 | 0.060 |
Why?
| T-Lymphocytes | 1 | 1985 | 373 | 0.060 |
Why?
| Cross Infection | 1 | 2004 | 107 | 0.060 |
Why?
| Intensive Care Units, Neonatal | 1 | 2004 | 117 | 0.060 |
Why?
| Aortic Valve | 1 | 1984 | 113 | 0.050 |
Why?
| Brain Abscess | 1 | 1982 | 11 | 0.050 |
Why?
| Nocardia Infections | 1 | 1982 | 4 | 0.050 |
Why?
| Phagocytes | 1 | 1982 | 11 | 0.050 |
Why?
| Cephalosporins | 1 | 1982 | 32 | 0.050 |
Why?
| Therapeutic Irrigation | 3 | 1987 | 27 | 0.050 |
Why?
| Clinical Protocols | 1 | 2003 | 122 | 0.050 |
Why?
| Retrospective Studies | 3 | 2010 | 6432 | 0.050 |
Why?
| Bone Diseases | 1 | 2003 | 109 | 0.050 |
Why?
| Animals | 6 | 2010 | 14385 | 0.050 |
Why?
| Drug Administration Schedule | 3 | 2007 | 401 | 0.050 |
Why?
| Skin Diseases | 1 | 2003 | 141 | 0.050 |
Why?
| Neutrophils | 2 | 1994 | 154 | 0.050 |
Why?
| Nontuberculous Mycobacteria | 1 | 2020 | 9 | 0.050 |
Why?
| Opportunistic Infections | 2 | 2000 | 58 | 0.050 |
Why?
| Young Adult | 1 | 2010 | 4318 | 0.050 |
Why?
| Outpatients | 1 | 2020 | 123 | 0.040 |
Why?
| Consensus | 1 | 2020 | 157 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 2 | 2007 | 1476 | 0.040 |
Why?
| Corneal Edema | 1 | 1999 | 4 | 0.040 |
Why?
| Anterior Chamber | 1 | 1999 | 10 | 0.040 |
Why?
| Conjunctiva | 1 | 1999 | 18 | 0.040 |
Why?
| Ophthalmic Solutions | 1 | 1999 | 27 | 0.040 |
Why?
| Antibodies, Bacterial | 1 | 1999 | 38 | 0.040 |
Why?
| Tomography Scanners, X-Ray Computed | 1 | 1998 | 14 | 0.040 |
Why?
| Spinal Diseases | 1 | 1998 | 20 | 0.040 |
Why?
| Soil Microbiology | 2 | 1987 | 23 | 0.040 |
Why?
| Spine | 1 | 1998 | 111 | 0.040 |
Why?
| Biopsy | 1 | 1999 | 692 | 0.040 |
Why?
| Child | 6 | 1993 | 7341 | 0.030 |
Why?
| Multicenter Studies as Topic | 1 | 1995 | 91 | 0.030 |
Why?
| Iron-Dextran Complex | 1 | 1994 | 3 | 0.030 |
Why?
| Serotyping | 1 | 1994 | 15 | 0.030 |
Why?
| Breast Diseases | 1 | 1995 | 24 | 0.030 |
Why?
| Breast | 1 | 1995 | 92 | 0.030 |
Why?
| Anaphylaxis | 1 | 1994 | 71 | 0.030 |
Why?
| Cytotoxicity, Immunologic | 1 | 1994 | 62 | 0.030 |
Why?
| Monocytes | 2 | 1985 | 156 | 0.030 |
Why?
| Macrophages, Alveolar | 1 | 1994 | 26 | 0.030 |
Why?
| Catheterization | 2 | 2003 | 108 | 0.030 |
Why?
| Desensitization, Immunologic | 1 | 1994 | 106 | 0.030 |
Why?
| Ecology | 2 | 1990 | 15 | 0.030 |
Why?
| Time Factors | 3 | 1985 | 3213 | 0.030 |
Why?
| Acridine Orange | 1 | 1991 | 2 | 0.030 |
Why?
| Gentian Violet | 1 | 1991 | 6 | 0.030 |
Why?
| Phenazines | 1 | 1991 | 4 | 0.030 |
Why?
| Urine | 1 | 2011 | 35 | 0.030 |
Why?
| Serum | 1 | 2011 | 39 | 0.030 |
Why?
| Staining and Labeling | 1 | 1991 | 106 | 0.020 |
Why?
| Trees | 1 | 1990 | 19 | 0.020 |
Why?
| Risk Assessment | 2 | 2007 | 1361 | 0.020 |
Why?
| Diet, Reducing | 1 | 1990 | 40 | 0.020 |
Why?
| Occupational Diseases | 1 | 1990 | 93 | 0.020 |
Why?
| Flucytosine | 1 | 1989 | 13 | 0.020 |
Why?
| Lung Diseases | 2 | 2000 | 86 | 0.020 |
Why?
| Cost-Benefit Analysis | 2 | 2000 | 291 | 0.020 |
Why?
| Wisconsin | 4 | 1990 | 43 | 0.020 |
Why?
| Tomography, X-Ray Computed | 2 | 1992 | 1213 | 0.020 |
Why?
| Lung | 2 | 1991 | 507 | 0.020 |
Why?
| Sinusitis | 1 | 1988 | 60 | 0.020 |
Why?
| Obesity | 2 | 1990 | 1202 | 0.020 |
Why?
| Bronchi | 1 | 1987 | 51 | 0.020 |
Why?
| Meningitis, Fungal | 1 | 2006 | 1 | 0.020 |
Why?
| Ethmoid Sinusitis | 1 | 2006 | 2 | 0.020 |
Why?
| Probability | 1 | 2007 | 176 | 0.020 |
Why?
| Echinococcosis | 1 | 1986 | 3 | 0.020 |
Why?
| Maxillary Sinusitis | 1 | 2006 | 13 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2007 | 232 | 0.020 |
Why?
| Swine Diseases | 1 | 1986 | 16 | 0.020 |
Why?
| Zoonoses | 1 | 1986 | 18 | 0.020 |
Why?
| Cerebrospinal Fluid | 1 | 2006 | 35 | 0.020 |
Why?
| Endocrine System Diseases | 1 | 1985 | 9 | 0.020 |
Why?
| Antitubercular Agents | 1 | 1986 | 90 | 0.020 |
Why?
| Leukocyte Count | 1 | 1985 | 77 | 0.020 |
Why?
| Nausea | 1 | 1985 | 52 | 0.020 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 1985 | 46 | 0.020 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1985 | 85 | 0.020 |
Why?
| Breast Neoplasms | 1 | 1995 | 1248 | 0.020 |
Why?
| Thymidine | 1 | 1984 | 18 | 0.020 |
Why?
| Follow-Up Studies | 2 | 2007 | 2387 | 0.020 |
Why?
| Cefazolin | 1 | 1984 | 11 | 0.020 |
Why?
| Mycobacterium tuberculosis | 1 | 1986 | 212 | 0.020 |
Why?
| Drug Resistance, Microbial | 1 | 1984 | 51 | 0.020 |
Why?
| Mitogens | 1 | 1984 | 16 | 0.020 |
Why?
| Blood-Borne Pathogens | 1 | 2004 | 8 | 0.020 |
Why?
| Heart Septal Defects, Ventricular | 1 | 1984 | 36 | 0.010 |
Why?
| Logistic Models | 1 | 2007 | 995 | 0.010 |
Why?
| Thumb | 1 | 1983 | 6 | 0.010 |
Why?
| Heart Valve Diseases | 1 | 1984 | 42 | 0.010 |
Why?
| Infant, Low Birth Weight | 1 | 2004 | 75 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2007 | 1084 | 0.010 |
Why?
| Infusions, Parenteral | 1 | 1982 | 21 | 0.010 |
Why?
| Biopsy, Needle | 2 | 1995 | 195 | 0.010 |
Why?
| Neutropenia | 1 | 2003 | 120 | 0.010 |
Why?
| Pregnancy | 2 | 2000 | 2620 | 0.010 |
Why?
| Leukemia, Lymphoid | 1 | 1982 | 6 | 0.010 |
Why?
| Bacteria | 1 | 1984 | 258 | 0.010 |
Why?
| Cohort Studies | 1 | 2007 | 1543 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2004 | 531 | 0.010 |
Why?
| Cell Migration Inhibition | 1 | 1981 | 2 | 0.010 |
Why?
| Phytohemagglutinins | 1 | 1981 | 12 | 0.010 |
Why?
| Cellulitis | 1 | 1981 | 15 | 0.010 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 1982 | 63 | 0.010 |
Why?
| Candida albicans | 1 | 1981 | 34 | 0.010 |
Why?
| Decision Making | 1 | 2004 | 290 | 0.010 |
Why?
| Survival Rate | 1 | 2004 | 951 | 0.010 |
Why?
| Double-Blind Method | 1 | 2003 | 742 | 0.010 |
Why?
| Piperazines | 1 | 1982 | 116 | 0.010 |
Why?
| Prospective Studies | 3 | 1995 | 2604 | 0.010 |
Why?
| Disseminated Intravascular Coagulation | 1 | 1980 | 8 | 0.010 |
Why?
| Imidazoles | 1 | 1982 | 142 | 0.010 |
Why?
| Mediastinitis | 1 | 2000 | 5 | 0.010 |
Why?
| Health Planning Guidelines | 1 | 2000 | 13 | 0.010 |
Why?
| Arthritis | 1 | 2000 | 49 | 0.010 |
Why?
| Pericarditis | 1 | 2000 | 21 | 0.010 |
Why?
| Central Nervous System Diseases | 1 | 2000 | 30 | 0.010 |
Why?
| Jejunum | 1 | 1980 | 56 | 0.010 |
Why?
| Ileum | 1 | 1980 | 102 | 0.010 |
Why?
| Kidney Transplantation | 1 | 1981 | 188 | 0.010 |
Why?
| Pregnancy Complications, Infectious | 1 | 2000 | 75 | 0.010 |
Why?
| Infant | 1 | 1988 | 3817 | 0.010 |
Why?
| Prognosis | 1 | 1983 | 2118 | 0.010 |
Why?
| Treatment Failure | 1 | 1997 | 139 | 0.010 |
Why?
| Postoperative Complications | 2 | 1981 | 1033 | 0.010 |
Why?
| Infant, Newborn | 1 | 2004 | 2907 | 0.010 |
Why?
| Pregnancy Complications | 1 | 2000 | 384 | 0.010 |
Why?
| Heart Failure | 1 | 1980 | 541 | 0.010 |
Why?
| Anemia, Iron-Deficiency | 1 | 1994 | 24 | 0.010 |
Why?
| Pilot Projects | 1 | 1995 | 808 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1991 | 107 | 0.010 |
Why?
| Rats, Inbred Strains | 1 | 1991 | 172 | 0.010 |
Why?
| Bacteriological Techniques | 1 | 1991 | 38 | 0.010 |
Why?
| Minnesota | 1 | 1990 | 27 | 0.010 |
Why?
| Ketosis | 1 | 1990 | 4 | 0.010 |
Why?
| Chemotaxis | 1 | 1990 | 28 | 0.010 |
Why?
| Antimycin A | 1 | 1990 | 7 | 0.010 |
Why?
| Fasting | 1 | 1990 | 76 | 0.010 |
Why?
| Skin Tests | 1 | 1990 | 58 | 0.010 |
Why?
| Regression Analysis | 1 | 1990 | 445 | 0.010 |
Why?
| Mucormycosis | 1 | 1988 | 28 | 0.010 |
Why?
| Acute Disease | 1 | 1990 | 403 | 0.010 |
Why?
| Aspergillosis | 1 | 1988 | 127 | 0.000 |
Why?
| Body Weight | 1 | 1990 | 578 | 0.000 |
Why?
| Immunodiffusion | 1 | 1987 | 3 | 0.000 |
Why?
| Complement Fixation Tests | 1 | 1987 | 4 | 0.000 |
Why?
| Corynebacterium Infections | 1 | 1986 | 1 | 0.000 |
Why?
| Blood Glucose | 1 | 1990 | 489 | 0.000 |
Why?
| Incidence | 1 | 1990 | 1082 | 0.000 |
Why?
| Fiber Optic Technology | 1 | 1986 | 17 | 0.000 |
Why?
| Weather | 1 | 1986 | 7 | 0.000 |
Why?
| Camping | 1 | 1986 | 3 | 0.000 |
Why?
| Epidemiologic Methods | 1 | 1986 | 49 | 0.000 |
Why?
| Dogs | 1 | 1986 | 217 | 0.000 |
Why?
| Swine | 1 | 1986 | 431 | 0.000 |
Why?
| Rats | 1 | 1991 | 3415 | 0.000 |
Why?
| Prednisolone | 1 | 1981 | 57 | 0.000 |
Why?
| Rural Population | 1 | 1986 | 600 | 0.000 |
Why?
| Mediastinal Diseases | 1 | 1980 | 7 | 0.000 |
Why?
| Tuberculosis | 1 | 1980 | 104 | 0.000 |
Why?
| Risk | 1 | 1980 | 343 | 0.000 |
Why?
| Sex Factors | 1 | 1980 | 767 | 0.000 |
Why?
|
|
Bradsher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|